LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
30 funds hold it · Insiders net selling
Net selling: insiders sold $33M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Oct 29, 2026
Financial period
Q3 2026
Earnings per share
-$3.87 expected
Revenue
$1.48B expected
FY 2026 guidance
$5.21B to $5.30B
No comparable estimate
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Oct 29, 2026 | -$3.60est. -$3.87 | +6.93%beat | $1.56Best. $1.48B+5.55% | +14.0%from $1.37B |
| Jun 30, 2026Reported Jul 28, 2026 | $3.09est. $2.15 | +43.95%beat | $1.67BCompany release | +37.7%from $1.22B |
| Mar 31, 2026Reported Apr 28, 2026 | $1.81est. $1.34 | +35.12%beat | $1.27BSEC filing | +20.9%from $1.05B |
| Dec 31, 2025Reported Feb 10, 2026 | $1.80est. $1.92 | -6.08%miss | $1.51BAlpha Vantage | +27.8%from $1.18B |
| Sep 30, 2025Reported Oct 28, 2025 | $2.26est. $1.64 | +37.80%beat | $1.37BSEC filing | +20.0%from $1.14B |
| Jun 30, 2025Reported Jul 29, 2025 | $1.57est. $1.47 | +6.80%beat | $1.22BSEC filing | +16.5%from $1.04B |
| Mar 31, 2025Reported Apr 29, 2025 | $1.16est. $1.03 | +12.62%beat | $1.05BSEC filing | +19.5%from $880.9M |
| Dec 31, 2024Reported Feb 10, 2025 | $1.43est. $1.55 | -7.74%miss | $1.18BAlpha Vantage | +16.3%from $1.01B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.51B | $1.27B | $1.67B | $1.56B |
| Cost of what it sold | $121.1M | $104.5M | $105.0M | $108.7M |
| Gross profit | $1.39B | $1.17B | $1.57B | $1.45B |
| What it spent | ||||
| Research and development | $611.4M | $515.9M | $517.0M | $1.79B |
| Sales and admin | $390.4M | $328.1M | $351.7M | $364.3M |
| Total operating expenses | $1.00B | $844.0M | $871.2M | $2.16B |
| What was left | ||||
| Operating profit | $384.0M | $324.2M | $697.9M | -$708.4M |
| Interest on debt | $582.0K | $569.0K | $581.0K | $605.0K |
| Profit before tax | $389.9M | $343.6M | $751.5M | -$688.8M |
| Tax | $90.7M | $40.3M | $165.9M | $96.0M |
| Net profit | $299.3M | $303.3M | $585.6M | -$784.8M |
| EBITDA | $414.5M | $368.0M | $778.6M | -$688.2M |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer
BullishNov 10Natera, Incyte partner on colorectal cancer trial using MRD test
NeutralNov 10Natera and Incyte team up on phase II colorectal cancer trial
BullishNov 10Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer
Leans bullishNov 10Is Neurocrine Biosciences (NBIX) Still Cheap As INGREZZA Data And Earnings Outlook Lift Sentiment?
Leans bullishNov 10Natera, Incyte Collaborate on Interventional Phase II Study in Colorectal Cancer
Leans bullishNov 10Incyte Raises Sales Outlook as Drug Revenue Climbs 14%
BullishNov 9The Strong Earnings Posted By Neurocrine Biosciences (NASDAQ:NBIX) Are A Good Indication Of The Strength Of The Business
NeutralNov 934 macro signals shaping INCY right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
